Cytokinetics (CYTK) Stock Forecast, Price Target & Predictions
CYTK Stock Forecast
Cytokinetics stock forecast is as follows: an average price target of $80.92 (represents a 44.81% upside from CYTK’s last price of $55.88) and a rating consensus of 'Buy', based on 13 wall street analysts offering a 1-year stock forecast.
CYTK Price Target
The average price target for Cytokinetics (CYTK) is $80.92 based on 1-year price targets from 13 Wall Street analysts in the past 3 months, with a price target range of $107.00 to $45.00. This represents a potential 44.81% upside from CYTK's last price of $55.88.
CYTK Analyst Ratings
According to 13 Wall Street analysts, Cytokinetics's rating consensus is 'Buy'. The analyst rating breakdown for CYTK stock is 0 'Strong Buy' (0.00%), 11 'Buy' (84.62%), 2 'Hold' (15.38%), 0 'Sell' (0.00%), and 0 'Strong Sell' (0.00%).
Cytokinetics Price Target by Analyst
| Date | Analyst | Company | Price Target | Price when Published | Price Target/Price when Published | Price Target/Last Closing Price |
|---|---|---|---|---|---|---|
| Sep 03, 2024 | Paul Choi | Goldman Sachs | $60.00 | $54.56 | 9.97% | 7.37% |
| Jun 10, 2024 | Yasmeen Rahimi | Piper Sandler | $107.00 | $53.21 | 101.09% | 91.48% |
| Jun 04, 2024 | Mayank Mamtani | B.Riley Financial | $92.00 | $48.70 | 88.91% | 64.64% |
| May 28, 2024 | Jason Butler | JMP Securities | $78.00 | $48.30 | 61.49% | 39.58% |
| May 23, 2024 | Joseph Pantginis | H.C. Wainwright | $90.00 | $48.71 | 84.77% | 61.06% |
| May 23, 2024 | Serge Belanger | Needham | $72.00 | $59.23 | 21.56% | 28.85% |
| May 23, 2024 | Akash Tewari | Jefferies | $85.00 | $59.23 | 43.51% | 52.11% |
| May 23, 2024 | Carter Gould | Barclays | $95.00 | $59.23 | 60.39% | 70.01% |
| May 09, 2024 | Justin Kim | Oppenheimer | $106.00 | $65.27 | 62.40% | 89.69% |
| May 09, 2024 | Jason Butler | JMP Securities | $106.00 | $65.27 | 62.40% | 89.69% |
The latest Cytokinetics stock forecast, released on Sep 03, 2024 by Paul Choi from Goldman Sachs, set a price target of $60.00, which represents a 9.97% increase from the stock price at the time of the forecast ($54.56), and a 7.37% increase from CYTK last price ($55.88).
Cytokinetics Price Target by Period
| 1M | 3M | 12M | |
|---|---|---|---|
| # Anlaysts | 1 | 1 | 11 |
| Avg Price Target | $60.00 | $60.00 | $90.00 |
| Last Closing Price | $55.88 | $55.88 | $55.88 |
| Upside/Downside | 7.37% | 7.37% | 61.06% |
In the current month, the average price target of Cytokinetics stock is $60.00, according to 1 Wall Street analyst offering twelve months forecast. The average price target represents a 7.37% increase as opposed to Cytokinetics's last price of $55.88. This month's average price target is down 0.00% compared to last quarter, and down -33.33% compared to last year.
Analyst Ratings Upgrades/Downgrades
| Date | Company | Previous Rating | New Rating | Rating Change |
|---|---|---|---|---|
| Sep 03, 2024 | Goldman Sachs | Neutral | Neutral | Hold |
| Aug 13, 2024 | Goldman Sachs | - | Neutral | Downgrade |
| Jun 10, 2024 | Piper Sandler | Overweight | Overweight | Hold |
| Jun 04, 2024 | B. Riley | Buy | Buy | Hold |
| May 23, 2024 | H.C. Wainwright | Buy | Buy | Hold |
| May 23, 2024 | Needham | Buy | Buy | Hold |
| May 23, 2024 | Jefferies | Buy | Buy | Hold |
| May 23, 2024 | Barclays | Overweight | Overweight | Hold |
| May 14, 2024 | Bank of America Securities | Neutral | Neutral | Hold |
| May 09, 2024 | Oppenheimer | Outperform | Outperform | Hold |
Cytokinetics's last stock rating was published by Goldman Sachs on Sep 03, 2024. The company gave CYTK a "Neutral" rating, the same as its previous rate.
Cytokinetics Financial Forecast
Cytokinetics Revenue Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jul 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | Sep 19 | Jun 19 | Mar 19 | Dec 18 | Sep 18 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | - | - | - | - | $378.00K | $867.00K | $4.61M | $1.96M | $2.52M | - | $1.15M | $55.60M | $5.44M | $2.84M | $6.55M | $6.72M | $41.69M | $3.59M | $3.83M | $5.21M | $6.05M | $7.14M | $8.46M | $9.38M | $10.64M |
| Avg Forecast | $16.72M | $4.77M | $1.75M | $500.00K | $5.93M | $1.23M | $7.61M | $912.85K | $7.62M | $20.24M | $5.67M | $2.08M | $7.10M | $3.51M | $3.73M | $4.34M | $5.80M | $5.98M | $5.52M | $6.57M | $23.76M | $4.02M | $4.07M | $5.01M | $7.20M | $7.52M | $6.99M | $6.86M | $10.16M | $13.57M |
| High Forecast | $16.72M | $4.77M | $1.75M | $500.00K | $5.93M | $6.57M | $7.61M | $912.85K | $39.92M | $20.24M | $5.67M | $2.08M | $7.10M | $3.51M | $3.73M | $5.27M | $7.03M | $7.25M | $6.69M | $7.97M | $28.80M | $4.87M | $4.94M | $6.07M | $8.72M | $9.12M | $8.47M | $8.32M | $12.19M | $16.28M |
| Low Forecast | $16.72M | $4.77M | $1.75M | $500.00K | $5.93M | $246.48K | $7.61M | $912.85K | $319.32K | $20.24M | $5.67M | $2.08M | $7.10M | $3.51M | $3.73M | $3.29M | $4.39M | $4.53M | $4.18M | $4.98M | $18.00M | $3.04M | $3.09M | $3.79M | $5.45M | $5.70M | $5.30M | $5.20M | $8.13M | $10.85M |
| # Analysts | 8 | 5 | 4 | 4 | 8 | 11 | 5 | 10 | 11 | 5 | 5 | 9 | 5 | 4 | 4 | 8 | 6 | 5 | 5 | 4 | 6 | 4 | 6 | 4 | 5 | 3 | 5 | 3 | 8 | 17 |
| Surprise % | - | - | - | - | - | - | - | - | - | 0.02% | 0.15% | 2.21% | 0.28% | 0.72% | - | 0.26% | 9.58% | 0.91% | 0.52% | 1.00% | 0.28% | 10.38% | 0.88% | 0.76% | 0.72% | 0.81% | 1.02% | 1.23% | 0.92% | 0.78% |
Cytokinetics's average Quarter revenue forecast for Dec 23 based on 11 analysts is $7.62M, with a low forecast of $319.32K, and a high forecast of $39.92M. CYTK's average Quarter revenue forecast represents a 1914.79% increase compared to the company's last Quarter revenue of $378.00K (Sep 23).
Cytokinetics EBITDA Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jul 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | Sep 19 | Jun 19 | Mar 19 | Dec 18 | Sep 18 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 8 | 5 | 4 | 4 | 8 | 11 | 5 | 10 | 11 | 5 | 5 | 9 | 5 | 4 | 4 | 8 | 6 | 5 | 5 | 4 | 6 | 4 | 6 | 4 | 5 | 3 | 5 | 3 | 8 | 17 |
| EBITDA | - | - | - | - | - | - | - | - | - | $-115.43M | $-115.27M | $-118.05M | $-121.11M | $-102.89M | - | $-77.44M | $-21.35M | $-68.51M | $-54.07M | $-39.78M | $-33.79M | $6.80M | $-30.56M | $-29.23M | $-21.98M | $-22.57M | $-25.39M | $-23.09M | $-20.88M | $-16.32M |
| Avg Forecast | $-16.72M | $-4.77M | $-1.75M | $-500.00K | $-5.93M | $-1.23M | $-7.61M | $-60.82M | $-7.62M | $-20.24M | $-5.67M | $-65.05M | $-7.10M | $-46.97M | $-3.73M | $-69.57M | $-30.19M | $-50.24M | $-36.60M | $-34.30M | $-27.13M | $-4.02M | $-24.66M | $-19.88M | $-7.20M | $-22.11M | $-22.34M | $-19.65M | $-22.48M | $-19.84M |
| High Forecast | $-16.72M | $-4.77M | $-1.75M | $-500.00K | $-5.93M | $-246.48K | $-7.61M | $-48.66M | $-319.32K | $-20.24M | $-5.67M | $-52.04M | $-7.10M | $-37.58M | $-3.73M | $-55.66M | $-24.15M | $-40.19M | $-29.28M | $-27.44M | $-21.70M | $-3.04M | $-19.73M | $-15.90M | $-5.45M | $-17.69M | $-17.88M | $-15.72M | $-17.99M | $-15.87M |
| Low Forecast | $-16.72M | $-4.77M | $-1.75M | $-500.00K | $-5.93M | $-6.57M | $-7.61M | $-72.99M | $-39.92M | $-20.24M | $-5.67M | $-78.06M | $-7.10M | $-56.37M | $-3.73M | $-83.49M | $-36.23M | $-60.29M | $-43.92M | $-41.16M | $-32.55M | $-4.87M | $-29.59M | $-23.85M | $-8.72M | $-26.53M | $-26.81M | $-23.58M | $-26.98M | $-23.81M |
| Surprise % | - | - | - | - | - | - | - | - | - | 5.70% | 20.35% | 1.81% | 17.06% | 2.19% | - | 1.11% | 0.71% | 1.36% | 1.48% | 1.16% | 1.25% | -1.69% | 1.24% | 1.47% | 3.06% | 1.02% | 1.14% | 1.18% | 0.93% | 0.82% |
6 analysts predict CYTK's average Quarter EBITDA for Dec 20 to be $-27.13M, with a high of $-21.70M and a low of $-32.55M. This is -499.06% lower than Cytokinetics's previous annual EBITDA (Sep 20) of $6.80M.
Cytokinetics Net Income Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jul 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | Sep 19 | Jun 19 | Mar 19 | Dec 18 | Sep 18 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 8 | 5 | 4 | 4 | 8 | 11 | 5 | 10 | 11 | 5 | 5 | 9 | 5 | 4 | 4 | 8 | 6 | 5 | 5 | 4 | 6 | 4 | 6 | 4 | 5 | 3 | 5 | 3 | 8 | 17 |
| Net Income | - | - | - | - | - | - | - | - | - | $-129.42M | $-128.64M | $-129.44M | $-131.46M | $-176.18M | - | $-101.03M | $-39.06M | $-76.09M | $-61.55M | $-47.10M | $-43.93M | $-3.17M | $-40.78M | $-39.41M | $-30.64M | $-29.57M | $-32.11M | $-29.37M | $-26.47M | $-22.02M |
| Avg Forecast | $-135.09M | $-141.28M | $-145.84M | $-145.29M | $-135.51M | $-135.06M | $-115.42M | $-69.04M | $-104.70M | $-81.15M | $-124.46M | $-73.84M | $-131.76M | $-52.17M | $-104.93M | $-78.98M | $-43.23M | $-55.80M | $-41.67M | $-40.61M | $-35.27M | $-5.29M | $-32.91M | $-26.80M | $-43.59M | $-28.97M | $-28.26M | $-24.99M | $-28.50M | $-26.77M |
| High Forecast | $-135.09M | $-141.28M | $-145.84M | $-145.29M | $-135.51M | $-115.76M | $-115.42M | $-55.24M | $-51.84M | $-81.15M | $-124.46M | $-59.08M | $-131.76M | $-41.74M | $-104.93M | $-63.18M | $-34.59M | $-44.64M | $-33.33M | $-32.49M | $-28.22M | $-4.24M | $-26.33M | $-21.44M | $-29.85M | $-23.18M | $-22.61M | $-19.99M | $-22.80M | $-21.41M |
| Low Forecast | $-135.09M | $-141.28M | $-145.84M | $-145.29M | $-135.51M | $-156.49M | $-115.42M | $-82.85M | $-149.43M | $-81.15M | $-124.46M | $-88.61M | $-131.76M | $-62.60M | $-104.93M | $-94.77M | $-51.88M | $-66.96M | $-50.00M | $-48.73M | $-42.32M | $-6.35M | $-39.49M | $-32.15M | $-55.61M | $-34.76M | $-33.91M | $-29.99M | $-34.20M | $-32.12M |
| Surprise % | - | - | - | - | - | - | - | - | - | 1.59% | 1.03% | 1.75% | 1.00% | 3.38% | - | 1.28% | 0.90% | 1.36% | 1.48% | 1.16% | 1.25% | 0.60% | 1.24% | 1.47% | 0.70% | 1.02% | 1.14% | 1.18% | 0.93% | 0.82% |
Cytokinetics's average Quarter net income forecast for undefined is $NaN, with a range of $NaN to $NaN. CYTK's average Quarter net income forecast represents a NaN% decrease compared to the company's last Quarter net income of $NaN (undefined).
Cytokinetics SG&A Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jul 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | Sep 19 | Jun 19 | Mar 19 | Dec 18 | Sep 18 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 8 | 5 | 4 | 4 | 8 | 11 | 5 | 10 | 11 | 5 | 5 | 9 | 5 | 4 | 4 | 8 | 6 | 5 | 5 | 4 | 6 | 4 | 6 | 4 | 5 | 3 | 5 | 3 | 8 | 17 |
| SG&A | - | - | - | - | - | - | - | - | - | $40.11M | $39.72M | $49.66M | $53.97M | $48.22M | - | $33.07M | $33.81M | $26.20M | $21.20M | $15.60M | $13.91M | $12.30M | $14.16M | $12.45M | $10.58M | $9.75M | $9.84M | $9.44M | $7.56M | $7.16M |
| Avg Forecast | $96.08M | $27.39M | $10.06M | $2.87M | $34.07M | $7.04M | $43.71M | $5.25M | $43.76M | $116.32M | $32.55M | $11.98M | $40.80M | $20.15M | $21.44M | $24.97M | $33.34M | $34.39M | $31.71M | $37.77M | $11.17M | $23.08M | $23.40M | $28.77M | $41.35M | $43.21M | $40.17M | $39.43M | $8.14M | $8.71M |
| High Forecast | $96.08M | $27.39M | $10.06M | $2.87M | $34.07M | $37.77M | $43.71M | $5.25M | $229.38M | $116.32M | $32.55M | $11.98M | $40.80M | $20.15M | $21.44M | $30.26M | $40.41M | $41.68M | $38.44M | $45.78M | $13.40M | $27.97M | $28.37M | $34.87M | $50.12M | $52.38M | $48.69M | $47.80M | $9.77M | $10.45M |
| Low Forecast | $96.08M | $27.39M | $10.06M | $2.87M | $34.07M | $1.42M | $43.71M | $5.25M | $1.84M | $116.32M | $32.55M | $11.98M | $40.80M | $20.15M | $21.44M | $18.92M | $25.26M | $26.05M | $24.02M | $28.61M | $8.93M | $17.48M | $17.73M | $21.79M | $31.32M | $32.74M | $30.43M | $29.87M | $6.51M | $6.97M |
| Surprise % | - | - | - | - | - | - | - | - | - | 0.34% | 1.22% | 4.15% | 1.32% | 2.39% | - | 1.32% | 1.01% | 0.76% | 0.67% | 0.41% | 1.25% | 0.53% | 0.61% | 0.43% | 0.26% | 0.23% | 0.24% | 0.24% | 0.93% | 0.82% |
Cytokinetics's average Quarter SG&A projection for Dec 23 is $43.76M, based on 11 Wall Street analysts, with a range of $1.84M to $229.38M. The forecast indicates a 9.11% rise compared to CYTK last annual SG&A of $40.11M (Sep 23).
Cytokinetics EPS Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jul 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | Sep 19 | Jun 19 | Mar 19 | Dec 18 | Sep 18 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 8 | 5 | 4 | 4 | 8 | 11 | 5 | 10 | 11 | 5 | 5 | 9 | 5 | 4 | 4 | 8 | 6 | 5 | 5 | 4 | 6 | 4 | 6 | 4 | 5 | 3 | 5 | 3 | 8 | 17 |
| EPS | - | - | - | - | - | - | - | - | - | $-1.35 | $-1.34 | $-1.36 | $-1.39 | $-1.88 | - | $-1.19 | $-0.46 | $-0.95 | $-0.86 | $-0.66 | $-0.62 | $-0.05 | $-0.68 | $-0.66 | $-0.52 | $-0.50 | $-0.56 | $-0.54 | $-0.48 | $-0.40 |
| Avg Forecast | $-1.24 | $-1.29 | $-1.33 | $-1.33 | $-1.24 | $-1.24 | $-1.06 | $-1.14 | $-0.96 | $-0.74 | $-1.14 | $-1.20 | $-1.21 | $-1.16 | $-1.03 | $-0.94 | $-0.85 | $-0.78 | $-0.66 | $-0.58 | $-0.43 | $-0.34 | $-0.57 | $-0.50 | $-0.44 | $-0.49 | $-0.50 | $-0.47 | $-0.56 | $-0.62 |
| High Forecast | $-1.24 | $-1.29 | $-1.33 | $-1.33 | $-1.24 | $-1.06 | $-1.06 | $-1.14 | $-0.47 | $-0.74 | $-1.14 | $-1.20 | $-1.21 | $-1.16 | $-1.03 | $-0.65 | $-0.58 | $-0.53 | $-0.45 | $-0.40 | $-0.30 | $-0.23 | $-0.39 | $-0.34 | $-0.30 | $-0.34 | $-0.34 | $-0.32 | $-0.45 | $-0.50 |
| Low Forecast | $-1.24 | $-1.29 | $-1.33 | $-1.33 | $-1.24 | $-1.43 | $-1.06 | $-1.14 | $-1.37 | $-0.74 | $-1.14 | $-1.20 | $-1.21 | $-1.16 | $-1.03 | $-1.20 | $-1.08 | $-0.99 | $-0.84 | $-0.74 | $-0.55 | $-0.43 | $-0.73 | $-0.64 | $-0.56 | $-0.63 | $-0.63 | $-0.60 | $-0.67 | $-0.74 |
| Surprise % | - | - | - | - | - | - | - | - | - | 1.82% | 1.18% | 1.13% | 1.15% | 1.62% | - | 1.26% | 0.54% | 1.22% | 1.30% | 1.13% | 1.43% | 0.15% | 1.20% | 1.32% | 1.17% | 1.02% | 1.13% | 1.15% | 0.86% | 0.65% |
According to undefined Wall Street analysts, Cytokinetics's projected average Quarter EPS for undefined is $NaN, with a low estimate of $NaN and a high estimate of $NaN. This represents a NaN% decrease compared to CYTK previous annual EPS of $NaN (undefined).
Cytokinetics Peer Comparison by Price Target
| Ticker | Company | Last Closing Price | Avg Price Target | Upside/Downside | Avg Rating |
|---|---|---|---|---|---|
| XFOR | X4 Pharmaceuticals | $0.71 | $3.67 | 416.90% | Buy |
| PLRX | Pliant Therapeutics | $12.00 | $39.71 | 230.92% | Buy |
| ARVN | Arvinas | $25.05 | $75.36 | 200.84% | Buy |
| ABOS | Acumen Pharmaceuticals | $2.60 | $7.00 | 169.23% | Buy |
| RLAY | Relay Therapeutics | $7.60 | $19.50 | 156.58% | Buy |
| EWTX | Edgewise Therapeutics | $18.83 | $48.00 | 154.91% | Buy |
| INZY | Inozyme Pharma | $6.00 | $14.67 | 144.50% | Buy |
| BDTX | Black Diamond Therapeutics | $6.19 | $14.75 | 138.29% | Buy |
| STOK | Stoke Therapeutics | $14.47 | $33.75 | 133.24% | Buy |
| CYTK | Cytokinetics | $55.88 | $80.92 | 44.81% | Buy |
| TERN | Terns Pharmaceuticals | $8.96 | $12.50 | 39.51% | Buy |
| DYN | Dyne Therapeutics | $34.06 | $43.88 | 28.83% | Buy |
| AMLX | Amylyx Pharmaceuticals | $2.62 | $3.33 | 27.10% | Buy |
| DICE | DICE Therapeutics | $47.55 | $60.00 | 26.18% | Buy |
| RVMD | Revolution Medicines, Inc. Warrant | $43.70 | $51.20 | 17.16% | Buy |
| BPMC | Blueprint Medicines | $88.90 | $101.50 | 14.17% | Buy |
| KRTX | Karuna Therapeutics | $329.83 | $257.50 | -21.93% | Buy |
CYTK Forecast FAQ
Is Cytokinetics a good buy?
Yes, according to 13 Wall Street analysts, Cytokinetics (CYTK) is considered a 'Buy'. The rating consensus is based on 0 'Strong Buy' and 11 'Buy' recommendations, accounting for 84.62% of CYTK's total ratings.
What is CYTK's price target?
Cytokinetics (CYTK) average price target is $80.92 with a range of $45 to $107, implying a 44.81% from its last price of $55.88. The data is based on 13 Wall Street analysts who provided a twelve-month price target estimate in the last three months.
Will Cytokinetics stock go up soon?
According to Wall Street analysts' prediction for CYTK stock, the company can go up by 44.81% (from the last price of $55.88 to the average price target of $80.92), up by 91.48% based on the highest stock price target, and down by -19.47% based on the lowest stock price target.
Can Cytokinetics stock reach $80?
CYTK's average twelve months analyst stock price target of $80.92 supports the claim that Cytokinetics can reach $80 in the near future.
What is Cytokinetics's current price target trend?
1 Wall Street analyst forecast a $60 price target for Cytokinetics (CYTK) this month, up 7.37% from its last price of $55.88. Compared to the last 3 and 12 months, the average price target increased by 7.37% and increased by 61.06%, respectively.
What are Cytokinetics's analysts' financial forecasts?
Cytokinetics's analysts financial forecasts for the fiscal year (Dec 2024) are as follows: average revenue is $15.68M (high $21.02M, low $14.7M), average EBITDA is $-75.585M (high $-62.441M, low $-93.097M), average net income is $-455M (high $-422M, low $-490M), average SG&A $90.08M (high $120.8M, low $84.45M), and average EPS is $-4.677 (high $-4.5, low $-4.873). CYTK's analysts financial forecasts for the fiscal year (Dec 2025) are as follows: average revenue is $23.74M (high $23.74M, low $23.74M), average EBITDA is $-23.736M (high $-23.736M, low $-23.736M), average net income is $-568M (high $-568M, low $-568M), average SG&A $136.4M (high $136.4M, low $136.4M), and average EPS is $-5.195 (high $-5.195, low $-5.195).
Did the CYTK's actual financial results beat the analysts' financial forecasts?
Based on Cytokinetics's last annual report (Dec 2023), the company's revenue was $7.53M, which missed the average analysts forecast of $35.61M by -78.85%. Apple's EBITDA was $-526M, beating the average prediction of $-98.573M by 433.86%. The company's net income was $-526M, beating the average estimation of $-384M by 36.99%. Apple's SG&A was $173.61M, missing the average forecast of $204.61M by -15.15%. Lastly, the company's EPS was $-5.45, beating the average prediction of $-4.04 by 34.90%. In terms of the last quarterly report (Sep 2023), Cytokinetics's revenue was $378K, missing the average analysts' forecast of $20.24M by -98.13%. The company's EBITDA was $-115M, beating the average prediction of $-20.241M by 470.26%. Cytokinetics's net income was $-129M, beating the average estimation of $-81.148M by 59.49%. The company's SG&A was $40.11M, missing the average forecast of $116.32M by -65.52%. Lastly, the company's EPS was $-1.35, beating the average prediction of $-0.743 by 81.73%